Free Nursing CE 2017‑2018 |


Basal Insulin as a Foundation of Diabetes Treatments: Innovative Approaches Free Diabetes CME
Live online February 1, 2017and April 5, 2017  and available on demand through October 5, 2017.
Posted by...Bernard Sklar, MD.
Free Diabetes CME Credit hours...2.0. (1,0 hour for each)
CME Credits Awarded by....Primary Care Network.
Instruction Type...Streaming Video Lecture and discussion.
Target Audiences...This program is intended for endocrinologists, primary care clinicians, physician assistants, nurse practitioners, pharmacists, certified diabetes educators and other health care providers who provide frontline glycemic management for type 2 diabetes and related conditions.
Educational material updated....April 5, 2017.
Expiration of CME credit...October 5, 2017.
Financial Support...Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.
After viewing the two presentations of Basal Insulin as a Foundation of Diabetes Treatments,  you will be better able to:
• Describe the pharmacokinetics and pharmacodynamics of the newer ultra-long basal and follow-on biologic ("biosimilar") insulin formulations and how these differ from older formulations
• Determine indications and methods to transition from analog basal insulin to ultra-long basal insulins and follow-on biologic ("biosimilar") basal insulins to help achieve individualized patient treatment goals
• Examine the evidence-based, guideline-driven protocols for therapeutic advancement to basal insulin therapy alone or in combination with other treatment modalities to achieve individualized patient goals
• Identify potential patient, provider, and health care system barriers to initiation and titration of established and newer basal insulins, and methods to overcome these barriers

The Best of Stroke Forum 2016  Free Stroke CME
Posted by...Bernard Sklar, MD. 
Free CME Credit Hours...0.5.
CME Credits Awarded by...Vindico Medical Education.
Cost for Credit...Free.
Instruction Type...Video Lectures.
Target Audience...Emergency medicine physicians, neurologists, emergency medicine residents, nurses, physician assistants, nurse practitioners, and other health care professionals involved in the treatment of patients with AIS.
Educational material last updated...November 10, 2016.
CME Credit Expires...November 9, 2017.
Financial Support...Genentech, Inc.
The Best of Stroke Forum 2016 consists of two brief lectures:
• Eligibility for IV Thrombolysis: A Review of Inclusion and Exclusion Criteria
• Stroke Therapy: Examining New Evidence
After competing The Best of Stroke Forum 2016, you should be better able to:
• Apply evidence-based criteria to the selection of candidates for thrombolytic therapy in AIS.
• Evaluate FDA labeling, current data, and clinical practice guidelines on the use of tissue plasminogen activator in the extended 3-hour to 4.5-hour post-onset window.
• Assess recent studies and guidelines on endovascular procedures for AIS.
• Determine the criteria for the concomitant or preferential use of tissue plasminogen activator in patients with AIS who are being considered for endovascular procedures.
• Incorporate shared decision making with patients and their families to improve education and assist in reducing delays in treatment and complications.

An Update on Fixed-Dose LAMA/LABA Inhalers in COPD
Posted by...Bernard Sklar, MD. Free Lung Cancer CME
Free Pulmonology CME Credit hours...2.0.
CME Credits Awarded by....The France Foundation
Instruction Type...Text-and-Graphics.
Target Audiences...This program is intended for health care professionals who treat and manage patients with COPD.
Educational material updated....September 30, 2016.
Expiration of CME credit...September 29, 2017.
Financial Support...Boehringer Ingelheim Pharmaceuticals, Inc.
An Update on Fixed-Dose LAMA/LABA Inhalers in COPD consists of written presentations by 4 experts on the use of Fixed-Dose Inhalers in COPD
Upon completion of An Update on Fixed-Dose LAMA/LABA Inhalers in COPD, you should be able to:
• Evaluate key efficacy data from clinical trials on new and emerging fixed-dose LAMA/LABA inhalers in COPD.
• Evaluate key safety data from clinical trials on new and emerging fixed-dose LAMA/LABA inhalers in COPD.
• Apply information on the efficacy and safety of new/emerging LAMA/LABA inhalers in COPD to specific clinical scenarios.

Alzheimer Disease (AD) and Its Complications: Best Practices, Emerging Therapies, and Barriers to Care Alzheimer's Disease CME
Posted by...Bernard Sklar, MD.
Alzheimer's Disease CME Credit hours...1.0.
CME Credits Awarded by....ScientiaCME.
Instruction Type...Streaming Video Lecture.
Target Audiences...Healthcare professionals specializing in: neurology, gerontology, internal medicine, palliative care, or those who otherwise commonly care for patients with AD or who frequently encounter them or their caregivers in practice.
Educational material updated...December 21, 2015.
Expiration of CME credit...December 21, 2017.
Financial Support...AVANIR.
Topics covered in Alzheimer Disease (AD) and Its Complications include:
Epidemiology of and risk factors for Alzheimer Disease (AD), Symptomatology and diagnosis of AD, Treatment in patients with AD, Complications and barriers to optimal care in patients with AD and many more.
After completing Alzheimer Disease (AD) and Its Complications, you will be able to:
• Describe what is presently known about the pathophysiology of AD and the challenges associated with diagnosis and treatment of AD.
• Evaluate a treatment plan for a specific patient based on degree of AD to optimize safety and efficacy, suggesting modifications for improvement.
• Identify the present treatment options currently available for management of AD and apply them to patient cases using evidence-based medicine.
• Describe emerging drug therapies in the treatment of AD.
• Describe barriers to care and suggest therapies for treating cognitive and behavioral complications secondary to AD
In order to get credit from ScientiaCME, you must first establish a username and password.